Less than two weeks after Boston Scientific prevailed in a transvaginal mesh lawsuit in Massachusetts, a Dallas jury hit the company for $73 million. The verdict came relatively quickly; according to media sources, the jury was in deliberation for no more than three hours - and the verdict was unanimous.
With the September 17th recommendations from a panel of Food and Drug Administration advisors that the agency impose strict new limitations on the multi-billion dollar testosterone drug industry, the secret behind the marketing of these products, like AndroGel®, has been revealed. The smoke and mirrors pitch that these drugs will help the average male feel more alive, more energetic, and more youthful has been sufficiently debunked.
Levin, Papantonio attorney Ned McWilliams answers client questions regarding Xarelto and the Xarelto lawsuit he recently filed against the drug’s manufacturer Janssen Pharmaceutical (a subsidiary of Johnson & Johnson) and its co-marketer Bayer Healthcare AG.
Q: Ned, what do you see as the central issue of the Xarelto lawsuit?
An interesting legal question has come up in a vaginal mesh lawsuit recently. It has to do with whether or not a third party that manufacturers one component of the device should share liability with the primary manufacturer that assembled and sold the final product.
Thanks to a slick ad campaign that would make Mad Men's Don Draper green with envy, a lot of men who believe they are suffering from “Low T” (whether or not they actually are) are risking serious health consequences in order to “T it up.”
There were a few more indications last month that at least some transvaginal lawsuit defendants may face criminal charges. A few months ago, the consumer advocate organization Corporate Action Network called upon U.S. Attorney General Eric Holder to initiate a criminal investigation into allegations that Johnson & Johnson, parent company of mesh manufacturer Ethicon, engaged in obstruction of justice when documents relating to its products went missing.
There's been a great deal in the media about the potentially harmful effects of testosterone supplements, particularly when they are taken by men who have no real medical need. These effects can include elevated risk for stroke and heart attack, which have led to a number of injury lawsuits in recent months. Men eager to regain their youth and virilty – or increase it – nonetheless seek out these treatments, egged on by clever ad campaigns with snappy phrases such as “T it up!”
Many small investors have lost their life savings because of the misconduct of UBS financial advisors regarding Puerto Rican municipal bond investments.
In recent years, various players in the pharmaceutical industry have introduced a new line of anticoagulant drugs (popularly known as “blood thinners,” although this is not quite accurate – read on) that have promised to make life much easier for physicians who treat patients at risk for stroke. A stroke of course is the result of a blood clot that cuts off blood supply to the brain, and can result in permanent injury and even death.
Endo, a subsidiary of American Medical Systems, recently announced that it will be paying out $830 million to settle around 20,000 transvaginal mesh lawsuit actions pending against it in multidistrict litigation. This is on top of over $54 million paid out last year as well as over $1 billion the company is holding in reserve to cover its legal costs.